Neurocrine Biosciences SG&A increased by 5.5% to $318.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.2%, from $276.50M to $318.50M. Over 4 years (FY 2021 to FY 2025), SG&A shows an upward trend with a 18.7% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2015
Last reportedQ1 2026May 5, 2026
How to read this metric
A rising ratio of SG&A to revenue may indicate inefficiency or aggressive expansion, while a falling ratio suggests improved operating leverage.
Detailed definition
Selling, general, and administrative expenses encompass the costs associated with the day-to-day operation of the busine...
Peer comparison
Standard operating expense category; peers with larger global sales forces typically show higher absolute SG&A levels.
Metric ID:
selling_general_and_administrativeHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $143.20M | $154.60M | $156.50M | $200.70M | $182.80M | $186.30M | $182.90M | $242.70M | $221.80M | $204.20M | $218.90M | $243.10M | $242.00M | $234.30M | $287.80M | $276.50M | $286.30M | $291.60M | $301.80M | $318.50M |
| QoQ Change | — | +8.0% | +1.2% | +28.2% | -8.9% | +1.9% | -1.8% | +32.7% | -8.6% | -7.9% | +7.2% | +11.1% | -0.5% | -3.2% | +22.8% | -3.9% | +3.5% | +1.9% | +3.5% | +5.5% |
| YoY Change | — | — | — | — | +27.7% | +20.5% | +16.9% | +20.9% | +21.3% | +9.6% | +19.7% | +0.2% | +9.1% | +14.7% | +31.5% | +13.7% | +18.3% | +24.5% | +4.9% | +15.2% |
Range$143.20M – $318.50M
CAGR+18.3%
Avg YoY Growth+16.8%
Median YoY Growth+17.6%
Current Streak4 quarters growth
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $276.50M | $286.30M | $291.60M | $301.80M | $318.50M |
| Total | $276.50M | $286.30M | $291.60M | $301.80M | $318.50M |
SG&A at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's sg&a?
- Neurocrine Biosciences (NBIX) reported sg&a of $318.50M in Q1 2026.
- How has Neurocrine Biosciences's sg&a changed year-over-year?
- Neurocrine Biosciences's sg&a increased by 15.2% year-over-year, from $276.50M to $318.50M.
- What is the long-term trend for Neurocrine Biosciences's sg&a?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's sg&a has grown at a 18.7% compound annual growth rate (CAGR), from $583.30M to $1.16B.
- What does sg&a mean?
- The overhead costs of running the business, including sales, marketing, and general corporate expenses.